KKKingsley Gideon Kumashie

Kingsley Gideon Kumashie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kingsley Gideon Kumashie has a total of 94 co-authors. Here are the top co-authors by number of shared publications:

  • Jakub Svoboda

    Department of Medicine, Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA

    2 shared publications
  • Laura A. Vella

    Division of Infectious Diseases, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

    2 shared publications
  • Raymone Pajarillo

    Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA

    2 shared publications
  • Aasha Gupta

    Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA

    1 shared publication
  • Aditi Gupta

    Division of Hematology/Oncology, Hospital of the University of Pennsylvania

    1 shared publication
  • Ajinkya Pattekar

    Center for Cellular Immunotherapies

    1 shared publication

Latest Publications

  • Open Access

    Multimodal analysis defines GNG4 as a distinguishing feature of germinal center-positioned CD4 T follicular helper cells in humans

    by Sam Barnett Dubensky, Yutong Zhu, Molly Gallagher, Kingsley Gideon Kumashie, Tianyu Lu, Jonathan Tedesco, Nina De Luna, Katherine Premo, Yi Qi, Suzanna Rachimi, et al.

    CD4 T follicular helper (Tfh) cells coordinate humoral immune responses within germinal centers (GC) of lymphoid tissue. Despite their critical roles in vaccination and autoimmunity, the gene expression programs that define functionally distinct human Tfh states—and the molecular pathways engaged by Tfh positioned within the GC niche—remain incompletely understood. This gap has limited translational efforts to monitor or therapeutically target specific Tfh states for clinical benefit. Here, we delineate human CD4 T cell heterogeneity in tonsils and peripheral blood using trimodal single-cell sequencing and spectral flow cytometry to define epigenomic, transcriptional, and proteomic features of distinct Tfh states. Tfh with a GC-like phenotype exhibited markedly increased chromatin accessibility and both mRNA and protein expression of G protein subunit gamma 4 ( GNG4 ). In tonsil, single-cell spatial transcriptomics defined GNG4 expression as a distinguishing feature of activated Tfh states within spatially demarcated GC compartments, with greater specificity than conventionally GC-associated features such as BCL6 , TOX2 , and S1PR2 . In contrast, GNG4 − Tfh primarily localized to nonGC regions and exhibited a resting, Th17-polarized phenotype. Together, these data highlight GNG4 as a central feature of activated, GC-positioned Tfh cell identity in humans.


  • The BTLA–HVEM axis restricts CAR T cell efficacy in cancer

    by Puneeth Guruprasad, Alberto Carturan, Yunlin Zhang, Jong Hyun Cho, Kingsley Gideon Kumashie, Ruchi P. Patel, Ki-Hyun Kim, Jong-Seo Lee, Yoon Lee, Jong Hoon Kim, et al.

    The efficacy of T cell-based immunotherapies is limited by immunosuppressive pressures in the tumor microenvironment. Here we show a predominant role for the interaction between BTLA on effector T cells and HVEM (TNFRSF14) on immunosuppressive tumor microenvironment cells, namely regulatory T cells. High BTLA expression in chimeric antigen receptor (CAR) T cells correlated with poor clinical response to treatment. Therefore, we deleted BTLA in CAR T cells and show improved tumor control and persistence in models of lymphoma and solid malignancies. Mechanistically, BTLA inhibits CAR T cells via recruitment of tyrosine phosphatases SHP-1 and SHP-2, upon trans engagement with HVEM. BTLA knockout thus promotes CAR signaling and subsequently enhances effector function. Overall, these data indicate that the BTLA–HVEM axis is a crucial immune checkpoint in CAR T cell immunotherapy and warrants the use of strategies to overcome this barrier.


  • Immunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia

    by Elise A Chong, Kingsley Gideon Kumashie, Emeline R Chong, Joseph Fabrizio, Aditi Gupta, Jakub Svoboda, Stefan K Barta, Kristy M Walsh, Ellen B Napier, Rachel K Lundberg, et al.

    Patients with B-cell lymphomas have altered cellular components of vaccine responses due to malignancy and therapy, and the optimal timing of vaccination relative to therapy remains unknown. Severe acute respiratory syndrome coronavirus 2 vaccines created an opportunity for new insights in vaccine timing because patients were challenged with a novel antigen across multiple phases of treatment. We studied serologic messenger RNA vaccine response in retrospective and prospective cohorts with lymphoma and chronic lymphocytic leukemia, paired with clinical and research immune parameters. Reduced serologic response was observed more frequently during active treatment, but nonresponse was also common within observation and posttreatment groups. Total immunoglobulin A and immunoglobulin M correlated with successful vaccine response. In individuals treated with anti-CD19–directed chimeric antigen receptor–modified T cells, nonresponse was associated with reduced B and T follicular helper cells. Predictors of vaccine response varied by disease and therapeutic group, and therefore further studies of immune health during and after cancer therapies are needed to individualize vaccine timing.